Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gemphire Therapeutics Inc    GEMP

GEMPHIRE THERAPEUTICS INC (GEMP)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Gemphire Therapeutics : Shares Fall Over 50% in Heavy Trading -- Market Mover

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/10/2018 | 05:19pm CEST

Gemphire Therapeutics Inc. (GEMP) saw its shares drop by over 50% in Friday trading, after the company announced the termination of a clinical trial of gemcabene. At 10:51 a.m. EDT, Gemphire shares had fallen to $1.38, down 57.80%, in heavy trading. Earlier in the week, the company announced it amended an agreement with Pfizer, Inc. concerning gemcabene. Shares opened the trading week at $7.55, and have been paused several times on Friday due to trading volatility. (stephen.nakrosis@wsj.com)

Stocks mentioned in the article
ChangeLast1st jan.
GEMPHIRE THERAPEUTICS INC 17.02% 1.65 Delayed Quote.-79.23%
PFIZER 1.62% 42.09 Delayed Quote.16.21%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GEMPHIRE THERAPEUTICS INC
08/17GEMPHIRE THERAPEUTICS : Announces Termination of Phase 2a Clinical Trial of Gemc..
AQ
08/14GEMPHIRE THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
08/13GEMPHIRE THERAPEUTICS INC. : Results of Operations and Financial Condition, Fina..
AQ
08/13Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provi..
GL
08/11GEMPHIRE THERAPEUTICS : shares plunge on forced termination of late-stage clinic..
AQ
08/11GEMPHIRE THERAPEUTICS : Announces Termination of Phase 2a Clinical Trial of Gemc..
AQ
08/10GEMPHIRE THERAPEUTICS INC. : Regulation FD Disclosure, Other Events, Financial S..
AQ
08/10GEMPHIRE THERAPEUTICS : Shares Fall Over 50% in Heavy Trading -- Market Mover
DJ
08/10GEMPHIRE THERAPEUTICS : Announces Amended and Restated Gemcabene License Agreeme..
AQ
08/10GEMPHIRE THERAPEUTICS : Provides Update on Development of Gemcabene
AQ
More news
News from SeekingAlpha
08/17Midday Gainers / Losers (08/17/2018) 
08/16HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (08/16/2018) 
08/13BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Gemphire Pulls Plug, Ampio's FDA Despair,.. 
08/13Gemphire Q2 cash at $28M 
08/13Gemphire Therapeutics beats by $0.08 
Financials ($)
Sales 2018 -
EBIT 2018 -27,2 M
Net income 2018 -30,4 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0
Capi. / Sales 2019 21,3x
Capitalization 23,5 M
Chart GEMPHIRE THERAPEUTICS INC
Duration : Period :
Gemphire Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GEMPHIRE THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 3,00 $
Spread / Average Target 82%
EPS Revisions
Managers
NameTitle
Steven R. Gullans President, Chief Executive Officer & Director
Charles L. Bisgaier Chairman & Chief Scientific Officer
Jeffrey S. Mathiesen CFO, Secretary & Principal Accounting Officer
Lee Scott Golden Chief Medical Officer
P. Kent Hawryluk Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GEMPHIRE THERAPEUTICS INC-79.23%23
GILEAD SCIENCES1.79%94 529
VERTEX PHARMACEUTICALS16.75%44 999
REGENERON PHARMACEUTICALS-1.11%39 726
NEUROCRINE BIOSCIENCES, INC.46.41%10 370
GENMAB2.28%9 923